PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
27.70%
EBIT growth above 1.5x AVXL's 15.87%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
27.70%
Operating income growth above 1.5x AVXL's 15.87%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
-117.18%
Negative net income growth while AVXL stands at 19.95%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-117.27%
Negative EPS growth while AVXL is at 19.35%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-117.27%
Negative diluted EPS growth while AVXL is at 19.35%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.72%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-138.72%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
64.97%
OCF/share CAGR of 64.97% while AVXL is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
64.97%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
27.61%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
64.19%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
64.19%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
-5.53%
Negative 3Y CAGR while AVXL is 26.60%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.11%
Negative 3Y equity/share growth while AVXL is at 54.72%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.50%
We have a declining book value while AVXL shows 21.18%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.88%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.